CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $43,950,005 | -12.2% | 2,736,613 | 0.0% | 1.61% | -24.0% |
| Q4 2022 | $50,080,018 | -30.7% | 2,736,613 | -25.6% | 2.11% | -29.2% |
| Q3 2022 | $72,255,000 | +5.3% | 3,678,947 | 0.0% | 2.98% | -9.9% |
| Q2 2022 | $68,612,000 | +4.1% | 3,678,947 | +22.5% | 3.31% | +25.6% |
| Q1 2022 | $65,935,000 | -22.7% | 3,003,879 | 0.0% | 2.64% | -14.8% |
| Q4 2021 | $85,340,000 | +325.0% | 3,003,879 | +214.9% | 3.10% | +295.7% |
| Q3 2021 | $20,079,000 | +4284.1% | 953,879 | +3828.7% | 0.78% | +4505.9% |
| Q2 2021 | $458,000 | – | 24,280 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |